FATE Fate Therapeutics Inc

Price (delayed)

$89.72

Market cap

$8.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.1

Enterprise value

$8.33B

Sector: Healthcare
Industry: Biotechnology

Highlights

The gross profit has surged by 194% year-on-year and by 71% since the previous quarter
FATE's revenue has surged by 194% year-on-year and by 71% since the previous quarter
The company's equity has surged by 57% YoY but it fell by 9% QoQ
The net income has plunged by 77% YoY and by 17% from the previous quarter
FATE's EPS is down by 46% year-on-year and by 14% since the previous quarter

Key stats

What are the main financial stats of FATE
Market
Shares outstanding
93.78M
Market cap
$8.41B
Enterprise value
$8.33B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
20.36
Price to sales (P/S)
235.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
264.97
Earnings
Revenue
$31.43M
EBIT
-$173.39M
EBITDA
-$170.3M
Free cash flow
-$44.16M
Per share
EPS
-$2.1
Free cash flow per share
-$0.54
Book value per share
$4.41
Revenue per share
$0.38
TBVPS
$7.56
Balance sheet
Total assets
$622.46M
Total liabilities
$238.01M
Debt
$97.3M
Equity
$384.45M
Working capital
$408.76M
Liquidity
Debt to equity
0.25
Current ratio
5.78
Quick ratio
5.89
Net debt/EBITDA
0.5
Margins
EBITDA margin
-541.8%
Gross margin
100%
Net margin
-551.6%
Operating margin
-407.5%
Efficiency
Return on assets
-31.2%
Return on equity
-46.2%
Return on invested capital
-55%
Return on capital employed
-32.3%
Return on sales
-551.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FATE stock price

How has the Fate Therapeutics stock price performed over time
Intraday
4%
1 week
-18.57%
1 month
0.46%
1 year
181.43%
YTD
-1.33%
QTD
-1.33%

Financial performance

How have Fate Therapeutics's revenue and profit performed over time
Revenue
$31.43M
Gross profit
$31.43M
Operating income
-$128.09M
Net income
-$173.39M
Gross margin
100%
Net margin
-551.6%
The gross profit has surged by 194% year-on-year and by 71% since the previous quarter
FATE's revenue has surged by 194% year-on-year and by 71% since the previous quarter
The net income has plunged by 77% YoY and by 17% from the previous quarter
The operating margin has soared by 57% YoY and by 40% from the previous quarter

Growth

What is Fate Therapeutics's growth rate over time

Valuation

What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
20.36
P/S
235.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
264.97
FATE's EPS is down by 46% year-on-year and by 14% since the previous quarter
FATE's price to book (P/B) is 94% higher than its last 4 quarters average of 10.5
The company's equity has surged by 57% YoY but it fell by 9% QoQ
FATE's revenue has surged by 194% year-on-year and by 71% since the previous quarter
The stock's price to sales (P/S) is 108% more than its 5-year quarterly average of 112.8 and 19% more than its last 4 quarters average of 198.3

Efficiency

How efficient is Fate Therapeutics business performance
FATE's return on sales is up by 39% year-on-year and by 32% since the previous quarter
The ROIC has grown by 31% YoY and by 6% from the previous quarter
Fate Therapeutics's return on assets has increased by 15% YoY
The ROE has grown by 7% YoY but it has contracted by 6% from the previous quarter

Dividends

What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FATE.

Financial health

How did Fate Therapeutics financials performed over time
FATE's total assets is 162% greater than its total liabilities
The company's quick ratio fell by 37% QoQ and by 26% YoY
FATE's current ratio is down by 37% from the previous quarter and by 29% YoY
The debt is 75% smaller than the equity
The company's debt to equity has surged by 127% YoY and by 25% QoQ
The company's equity has surged by 57% YoY but it fell by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.